BioWorld MedTech

July 23, 2015

St. Jude, Thoratec show a lot of Heart in transaction: St. Jude shows it has 'heart' with proposed $3.4B Thoratec acquisition

St. Jude Medical (NYSE:STJ) (St. Paul, Minn.) said that it has agreed to acquire Thoratec (NASDAQ:THOR) (Pleasanton, Calif.) for $63.50 per share in a cash transaction valued at about $3.4 billion. Read More

Inside the Beltway: Harmonization of GCPs seen as sticking point for OUS trials draft

Government programs still solvent: Balancing act: Trustees say Part A trust fund solvent through 2030

India's first materiovigilance program: India launches first program to track adverse effects of devices

BSX Initiates Fast Study: New generation bioabsorbable scaffolds may challenge DES

Financings: MedGenome receives $20M investment in Series B round

Agreements/contracts: Syngnis pulls a Double Switch with Thermo Fisher Scientific

People in places

Product briefs

Briefly Noted

MDD's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for July 7, 2026.

CINP 2026: Prenatal and adolescent stress shape brain vulnerability

BioWorld Science

Human biology is extraordinarily complex, and that sophistication emerges from the very beginning. During embryonic and fetal development, the organism’s...

Illustration of brain and brain waves, concept of focal seizure

Hyperexcitability may be joint problem in epilepsy, dementia

BioWorld

The majority of epilepsies are developmental disorders that start in childhood. But there is a large minority that starts in late adulthood. And increasingly,...

3D rendering of an antibody drug conjugate

‘Target-high but uptake-defective’ state identified in ADC resistance

BioWorld

Separate research teams have reported new insights into resistance mechanisms to the antibody-drug conjugate (ADC) Padcev (enfortumab vedotin, Astellas Pharma...

Modius Spero wearable neuromodulation device

Neurovalens granted FDA approval for PTSD therapy for US veterans

BioWorld

Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...